Information Provided By: 
Fly News Breaks for December 26, 2017
LJPC
Dec 26, 2017 | 07:45 EDT
SunTrust analyst Yatin Suneja raised his price target on La Jolla to $65 following the company's update on Giapreza. Suneja contends that the better than expected label granted to the treatment by the FDA implies better market opportunity than modeled by the Street. The analyst also keeps his Buy rating on La Jolla.
News For LJPC From the Last 2 Days
There are no results for your query LJPC
